Scholar Rock Holding Corporation - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SRRK Nasdaq 2830 www.scholarrock.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scholar Rock Holding Corporation

Scholar Rock to Present at Upcoming Investor Conferences - Nov 3rd, 2026 6:00 am
Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet Hopes - Oct 30th, 2026 3:13 am
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 - Oct 20th, 2026 6:00 am
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 16th, 2026 2:15 pm
EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK) - Oct 15th, 2026 7:20 pm
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - Oct 8th, 2026 6:00 am
3 drug targets pharma is betting on next - Oct 2nd, 2026 7:00 am
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals - Sep 28th, 2026 4:44 am
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says - Sep 25th, 2026 10:35 am
This week in charts: GSK’s China deals, the $300M IPO club and selling the news - Sep 18th, 2026 4:43 am
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale? - Sep 16th, 2026 10:06 pm
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions - Sep 15th, 2026 5:16 pm
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says - Sep 15th, 2026 12:52 pm
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy - Sep 14th, 2026 8:30 pm
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets - Sep 14th, 2026 2:30 pm
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says - Sep 14th, 2026 10:17 am
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy - Sep 14th, 2026 6:08 am
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump - Sep 14th, 2026 5:41 am
Scholar Rock SMA drug approved by FDA - Sep 14th, 2026 3:00 am